知搜-全球专利检索

  1. 登录
  2. 注册
发明公开
CN109091493A LncRNA ZEB1-AS1在制备改善卵巢上皮癌耐药药物中的应用 有权

LncRNA ZEB1-AS1在制备改善卵巢上皮癌耐药药物中的应用
摘要：
本发明公开药物组合物包括一种或多种活性成分：LncRNA-ZEB1-AS1或经过修饰的LncRNA-ZEB1-AS1；si-ZEB1-AS1或经过修饰的si-ZEB1-AS1；表达载体。本发明还公开LncRNAZEB1-AS1在制备改善卵巢上皮癌耐药药物中的应用。lncRNA ZEB1-AS1在耐药的卵巢上皮癌细胞A2780/R细胞中低表达，而在敏感卵巢上皮癌细胞A2780高表达，在有紫杉醇或者顺铂存在情况下，使用siRNA敲除ZEB1-AS1后，卵巢上皮癌耐药细胞明显对紫杉醇和顺铂敏感，使用过表达质粒转染之后，卵巢上皮癌敏感细胞A2780明显对紫杉醇和顺铂耐药。
摘要（英）：

The invention discloses pharmaceutical composition. The pharmaceutical composition contains one or more of active ingredients: LncRNA(long non-coding RNA)-ZEB1-AS1 or modified LncRNA-ZEB1-AS1, si-ZEB1-AS1 or modified si-ZEB1-AS1 and an expression vector. The invention further discloses an application of LncRNA ZEB1-AS1 in preparation of a drug for improving drug resistance of OEC (ovarian epithelial cancer). LncRNA ZEB1-AS1 has low expression in drug-resistant OEC cells A2780/R but has high expression in sensitive OEC cells A2780, in the presence of paclitaxel or cis-platinum, the drug-resistant OEC cells are obviously sensitive to paclitaxel and cis-platinum after ZEB1-AS1 is knocked out by siRNA, and the sensitive OEC cells A2780 are obviously drug-resistant to paclitaxel and cis-platinum after transfection with overexpressed plasmids.

公开/授权文献
0/0